Denka Company Limited(4061) News

Notice Concerning Change in Equity-Method Affiliate (Becoming a Consolidated Subsidiary)

(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc.”

Feb 27, 2026 Management Presentation Management Plan Mission 2030 Phase 2 (FY2026～FY2028)

Notice of Commencement of Consideration of Spin-off of Styrene-Related Businesses

Notice of Formulation of Management Plan “Mission 2030” Phase 2 (FY2026～FY2028)

[Delayed]Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)

Notice Regarding Recognition of Extraordinary Losses

Notice Regarding Personnel Changes in Executive Officers

Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP)

Results Presentation of FY2025 3Q

Notice Regarding Recognition of Extraordinary Losses

Results Presentation of FY2025 2Q (Financial Results and Topic: Direction of Management Plan Mission 2030 Revision)

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP)

Notice on Difference Between Consolidated Financial Results Forecast for the First Half of the Fiscal Year Ending March 31, 2026 and Actual Results

[Delayed]Corporate Governance Report

Results Presentation of FY2025 1Q

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP)

Announcement Concerning the Recording of Extraordinary Losses of a U.S. Subsidiary and of the Suspension of Chloroprene Rubber Production

Notice Concerning Difference Between Consolidated Earnings Forecast and Actual Results and Voluntary Return of Part of Executive Compensation

Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)